Kestra Medical Technologies CEO sells $692k in shares By Investing.com

Brian Daniel Webster, President and Chief Executive Officer at KESTRA MEDICAL TECHNOLOGIES, LTD. (), sold common shares worth approximately $692,214 in a series of transactions between July 30 and August 3, 2026. The shares were sold at prices ranging from $22.6039 to $23.9244 per share. These sales were non-discretionary, executed to satisfy tax withholding obligations related to the vesting and settlement of restricted stock units.

Specifically, Mr. Webster disposed of 7,857 common shares on July 30, 2026. An additional 8,948 common shares were sold on July 31, 2026. The final reported transaction in this filing occurred on August 3, 2026, involving the sale of 13,017 common shares. Following these transactions, Mr. Webster directly holds 527,115 common shares in Kestra Medical Technologies.The transactions come as KMTS stock trades at $23.99, up 55% over the past year but down 9.5% year-to-date. According to InvestingPro analysis, the stock appears overvalued relative to its Fair Value estimate, placing it among companies on the most overvalued list. The company, which generated $95.13 million in revenue over the last twelve months with 59% growth, remains unprofitable with analysts not expecting profitability this year. InvestingPro offers 6 additional exclusive tips for KMTS investors.

In other recent news, Kestra Medical Technologies reported a significant increase in revenue for its fiscal fourth quarter of 2026, with total revenue reaching $28.64 million, marking a 66% rise from the previous year. Despite the revenue surge, the company reported an adjusted earnings per share loss of $0.67, falling short of the forecasted loss of $0.58. The growth in revenue was largely driven by a substantial increase in prescriptions for the ASSURE wearable cardioverter-defibrillator. Stifel reiterated its Buy rating on Kestra Medical, maintaining a price target of $30.00, following these strong fiscal results. Wolfe Research also raised its price target from $29.00 to $30.00, citing the company’s execution exceeding expectations. Additionally, Oppenheimer initiated coverage on Kestra Medical with a Perform rating, highlighting a large total addressable market and continued market share gains. These developments reflect Kestra Medical’s ongoing expansion and investment in its product offerings and market presence.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.